AZD 7648
Alternative Names: AZD-7648Latest Information Update: 24 Jun 2025
At a glance
- Originator AstraZeneca
- Class Antineoplastics
- Mechanism of Action DNA-activated protein kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Soft tissue sarcoma; Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamic data from a preclinical biomarker study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)
- 07 Dec 2022 AstraZeneca and PAREXEL completes a phase I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA and United Kingdom (PO) (NCT03907969)